Covalent Modification of Cell Surfaces with TLR Agonists Improves & Directs Immune Stimulation

Overview

Journal Chem Commun (Camb)

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2013 Sep 12

PMID 24022092

Citations 10

Authors

Janine K Tom

Rock J Mancini

Aaron P Esser-Kahn

Affiliations

Soon will be listed here.

Abstract

We present a primary example of a cell surface modified with a synergistic combination of agonists to tune immune stimulation. A model cell line, Lewis Lung Carcinoma, was covalently modified with CpG-oligonucleotides and lipoteichoic acid, both Toll-like receptor (TLR) agonists. The immune-stimulating constructs provided greater stimulation of NF-κB in a model cell line and bone marrow-derived dendritic cells than the components unconjugated in solution.

Citing Articles

Toll-like Receptor Agonist Conjugation: A Chemical Perspective.

Ignacio B, Albin T, Esser-Kahn A, Verdoes M Bioconjug Chem. 2018; 29(3):587-603.

PMID: 29378134 PMC: 10642707. DOI: 10.1021/acs.bioconjchem.7b00808.

Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.

Li P, Fan Z, Cheng H Bioconjug Chem. 2018; 29(3):624-634.

PMID: 29323870 PMC: 5916811. DOI: 10.1021/acs.bioconjchem.7b00669.

Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.

Fan Y, Kuai R, Xu Y, Ochyl L, Irvine D, Moon J Nano Lett. 2017; 17(12):7387-7393.

PMID: 29144754 PMC: 5821496. DOI: 10.1021/acs.nanolett.7b03218.

Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.

Zhang W, An M, Xi J, Liu H Bioconjug Chem. 2017; 28(7):1993-2000.

PMID: 28644608 PMC: 6886672. DOI: 10.1021/acs.bioconjchem.7b00313.

Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates.

Zhang P, Andorko J, Jewell C Biotechnol Bioeng. 2016; 114(2):423-431.

PMID: 27567213 PMC: 6033025. DOI: 10.1002/bit.26083.

References

Murelli R, Zhang A, Michel J, Jorgensen W, Spiegel D . Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer. J Am Chem Soc. 2009; 131(47):17090-2. PMC: 2794306. DOI: 10.1021/ja906844e. View

Shukla N, Salunke D, Balakrishna R, Mutz C, Malladi S, David S . Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS One. 2012; 7(8):e43612. PMC: 3429503. DOI: 10.1371/journal.pone.0043612. View

Popkov M, Gonzalez B, Sinha S, Barbas 3rd C . Instant immunity through chemically programmable vaccination and covalent self-assembly. Proc Natl Acad Sci U S A. 2009; 106(11):4378-83. PMC: 2649956. DOI: 10.1073/pnas.0900147106. View

Pulendran B . Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev. 2004; 199:227-50. DOI: 10.1111/j.0105-2896.2004.00144.x. View

Pulendran B, Artis D . New paradigms in type 2 immunity. Science. 2012; 337(6093):431-5. PMC: 4078898. DOI: 10.1126/science.1221064. View

Shukla N, Mutz C, Malladi S, Warshakoon H, Balakrishna R, David S . Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines. J Med Chem. 2012; 55(3):1106-16. PMC: 3276691. DOI: 10.1021/jm2010207. View

Pulendran B . Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009; 9(10):741-7. DOI: 10.1038/nri2629. View

Vollmer J, Krieg A . Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009; 61(3):195-204. DOI: 10.1016/j.addr.2008.12.008. View

Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning C . Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999; 274(25):17406-9. DOI: 10.1074/jbc.274.25.17406. View

10.

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

11.

Underhill D, Bassetti M, Rudensky A, Aderem A . Dynamic interactions of macrophages with T cells during antigen presentation. J Exp Med. 1999; 190(12):1909-14. PMC: 2195713. DOI: 10.1084/jem.190.12.1909. View

12.

Levitz S, Golenbock D . Beyond empiricism: informing vaccine development through innate immunity research. Cell. 2012; 148(6):1284-92. PMC: 3308125. DOI: 10.1016/j.cell.2012.02.012. View

13.

Deininger S, Figueroa-Perez I, Sigel S, Stadelmaier A, Schmidt R, Hartung T . Use of synthetic derivatives to determine the minimal active structure of cytokine-inducing lipoteichoic acid. Clin Vaccine Immunol. 2007; 14(12):1629-33. PMC: 2168384. DOI: 10.1128/CVI.00007-07. View

14.

Matheu M, Sen D, Cahalan M, Parker I . Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging. J Vis Exp. 2008; (17). PMC: 3278326. DOI: 10.3791/773. View

15.

Krieg A . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60. DOI: 10.1146/annurev.immunol.20.100301.064842. View

16.

Moon J, Huang B, Irvine D . Engineering nano- and microparticles to tune immunity. Adv Mater. 2012; 24(28):3724-46. PMC: 3786137. DOI: 10.1002/adma.201200446. View

17.

De Geest B, Willart M, Lambrecht B, Pollard C, Vervaet C, Remon J . Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. Angew Chem Int Ed Engl. 2012; 51(16):3862-6. DOI: 10.1002/anie.201200048. View

18.

Moon J, Suh H, Li A, Ockenhouse C, Yadava A, Irvine D . Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A. 2012; 109(4):1080-5. PMC: 3268296. DOI: 10.1073/pnas.1112648109. View

19.

Janeway Jr C, Medzhitov R . Innate immune recognition. Annu Rev Immunol. 2002; 20:197-216. DOI: 10.1146/annurev.immunol.20.083001.084359. View

20.

Krieg A . The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000; 12(1):35-43. DOI: 10.1016/s0952-7915(99)00048-5. View